Congenital Heart Disease (CHD) Market Trends, Future Scope, Opportunities and Challenges

Congenital Heart Disease (CHD) Market research report provides an analytical measurement of the main challenges faced by the business currently and in the upcoming years. This market report also offers a profound overview of product specification, technology, product type and production analysis by taking into account most important factors such as revenue, cost, and gross margin. Proficient capabilities and excellent resources in research, data collection, development, consulting, evaluation, compliance and regulatory services come together to generate this world-class market research report. This Congenital Heart Disease (CHD) Market report is especially designed by keeping in mind the customer requirements which will ultimately assist them in boosting their return on investment (ROI).

Request For Free Sample Report at: https://www.delvens.com/get-free-sample/congenital-heart-disease-chd-market

Congenital Heart Disease (CHD) Market, by Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Others), Diagnosis (Electrocardiogram, Chest X-ray, Echocardiogram, Transoesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac CT Scan or MRI, Cardiac Catheterization, Other), Treatment (Medications, Surgery, Watchful Waiting, Others), Route of Administration (Oral, Parenteral, Others), End Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The Congenital Heart Disease (CHD) market size was estimated at USD 4.47 billion in 2023 and is projected to reach USD 8.11 billion in 2030 at a CAGR of 8.87% during the forecast period 2023-2030.

Congenital Heart Disease (CHD) Market Competitive Landscape:

Abbott Laboratories

AstraZeneca Plc

Becton Dickson & Co.

Bio-Rad Laboratories

Boston Scientific Corp.

Laboratory Corporation of America Holdings (LabCorp)

F. Hoffmann-La Roche Ltd.

Glaxosmithkline Plc

Janssen Pharmaceuticals, Inc.

Medtronic

Viatris Inc.

Novartis Ag

Pfizer, Inc.

Randox Laboratories Ltd.

Response Biomedical Corporation

Sanofi S.A.

Siemens Healthineers

Thermo Fisher Scientific Inc.

Vericel Corporation

Congenital Heart Disease (CHD) is a term used to describe a range of structural defects in the heart that are present at birth. These defects can involve the walls, valves, arteries, or veins of the heart, causing problems with blood flow and affecting the heart’s ability to pump blood effectively. Some congenital heart defects are mild and may not require treatment, while others can be more severe and require medical interventions such as surgery or medication. The exact cause of most congenital heart defects is not known, but a combination of genetic and environmental factors is thought to play a role.

The growth of the global Congenital Heart Disease (CHD) Market is mainly driven by rising prevalence of congenital heart disease globally. Moreover, increased awareness, improved diagnostic techniques, increased awareness and better access to healthcare are expected to drive the market further. In addition, the growing emphasis on paediatric cardiology and specialized care for children are expected to drive the market further during the forecast period.

Direct Purchase of the Congenital Heart Disease (CHD) Market Research Report at: https://www.delvens.com/checkout/congenital-heart-disease-chd-market

Congenital Heart Disease (CHD) Market Key Findings:

Based on type, the market is segmented into heart valve defects, heart wall defects, blood vessel defects, others. The heart wall defects dominated the market in this segment. This is due to the increase in the cases of Ventricular septal defect (VSD) or hole in the heart worldwide.

Based on diagnosis, the market is bifurcated into electrocardiogram, chest x-ray, echocardiogram, transoesophageal echocardiogram, pulse oximetry, exercise stress test, cardiac CT scan or MRI, cardiac catheterization, others. Electrocardiogram dominated the market in this segment. This is because Electrocardiogram is the most common diagnostic tool to diagnose heart defects.

Based on treatment, the market is segmented into medications, surgery, watchful waiting, others. Surgery dominated the market in this segment as it is the most common treatment for CHD. Surgical treatment can be performed open-heart surgery or minimally invasive surgery.

Based on route of administration, the market is segmented into oral, parenteral, others. Oral route of administration dominated the market in this segment. Oral is the most common route of administration for medications. Medications taken by the mouth are absorbed into the bloodstream through the digestive system.

Based on end users, the market is segmented into hospitals, specialty clinics, others. Based on end users, the market is dominated by hospitals. This is because diagnosis and treatment of CHD is most prevalent in hospitals.

Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, others. Hospital pharmacies dominated the market in this segment. This can be attributed to the fact that treatment for CHD are more prevalent in hospitals.

The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period due to the high prevalence of congenital heart disease and technological advancements in early diagnosis of the disease.

Congenital Heart Disease (CHD) Market Regional Analysis:

North America to Dominate the Market

North America is estimated to account for the largest market share during the forecast period. This is due to the high prevalence of congenital heart disease and technological advancements in early diagnosis of the disease.

Moreover, the strong presence of the key players in the region is expected to drive the market during the forecast period.

Congenital Heart Disease (CHD) Market Recent Developments:

In June 2023, Pfizer relaunched Eliquis, an anticoagulant used to prevent the gradual increase in the prevalence of stroke due to heart condition called atrial fibrillation which is a major concern being a common cause of death among adults.

In July 2023, Novartis announced that the US Food and Drug Administration (FDA) approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy.

Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/congenital-heart-disease-chd-market

Browse Related Reports:

Point of Care Testing Market

 Assisted Living (AL) Market

Next Generation Sequencing (NGS) Market

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

[email protected]